Likely would have more dilution without it, would likely have seen annual CRs in lieu of COVID testing, and with COVID but without COVID testing these would have been at a much lower level given the impact COVID has had on non-COVID medical stocks. Although, I agree, it would have been better to have distributed the COVID testing more widely (outside Aus) but surely this wasn't from lack of trying?
Ann: Chairman's Address to Shareholders, page-24
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
75.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $169.9M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1318 | 74.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 75.5¢ | 15000 | 1 |
View Market Depth
| Last trade - 10.10am 09/08/2024 (20 minute delay) ? |
| GSS (ASX) Chart |
Day chart unavailable